Day One Biopharmaceuticals (NASDAQ:DAWN) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note published on Tuesday morning, RTT News reports. They currently have a $33.00 target price on the stock.

Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an overweight rating in a research report on Monday, April 22nd. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a report on Tuesday, February 27th. Oppenheimer restated a market perform rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Needham & Company LLC reaffirmed a buy rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday. Finally, HC Wainwright lowered their price target on Day One Biopharmaceuticals from $50.00 to $40.00 and set a buy rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of Moderate Buy and a consensus price target of $37.67.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $17.08 on Tuesday. Day One Biopharmaceuticals has a twelve month low of $9.67 and a twelve month high of $18.07. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -7.18 and a beta of -1.44. The firm’s 50 day moving average price is $15.47 and its two-hundred day moving average price is $14.12.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, research analysts forecast that Day One Biopharmaceuticals will post -2.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 52,183 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $17.89, for a total transaction of $933,553.87. Following the completion of the transaction, the chief financial officer now owns 225,571 shares of the company’s stock, valued at approximately $4,035,465.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Charles N. York II sold 52,183 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.89, for a total transaction of $933,553.87. Following the transaction, the chief financial officer now directly owns 225,571 shares of the company’s stock, valued at approximately $4,035,465.19. The disclosure for this sale can be found here. Insiders sold a total of 195,247 shares of company stock valued at $3,376,817 in the last quarter. Insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DAWN. China Universal Asset Management Co. Ltd. raised its position in shares of Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the last quarter. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals in the fourth quarter worth about $29,000. Quintet Private Bank Europe S.A. raised its position in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank raised its position in Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after purchasing an additional 2,268 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its position in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after purchasing an additional 2,554 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.